Država: Australija
Jezik: engleski
Izvor: Department of Health (Therapeutic Goods Administration)
sodium chloride, Quantity: 8.6 g/L; calcium chloride dihydrate, Quantity: 330 mg/L; potassium chloride, Quantity: 300 mg/L
Baxter Healthcare Pty Ltd
Injection, intravenous infusion
Excipient Ingredients: sodium hydroxide; water for injections; hydrochloric acid
Intravenous
1000mL x 12
Not scheduled. Not considered by committee
For restoring the loss of water and electrolytes as required by the clinical condition of the patient.
Visual Identification: Clear colourless solution; Container Type: Bag; Container Life Time: 24 Months; Container Temperature: Store below 30 degrees Celsius
Registered
1991-09-30
CMI BAXTER Page 1 of 2 RINGER’S SOLUTION INTRAVENOUS INFUSION CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some common questions about RINGER’S SOLUTION IV INFUSION. It does not contain all of the available information. All medicines have risks and benefits. Your doctor has weighed the risks of you using Ringer’s Solution IV Infusion against the benefit they expect it will have for you. It does not take the place of talking to your doctor or pharmacist. If you have any concerns about taking this medicine, ask your doctor or pharmacist. WHAT RINGER’S SOLUTION IV INFUSION IS USED FOR This medicine is used to replace and balance body fluid and mineral salts. BEFORE YOU ARE GIVEN RINGER’S SOLUTION IV INFUSION _THE RINGER’S SOLUTION IV _ _INFUSION SHOULD NOT BE _ _GIVEN TO YOU IF: _ you have an allergy to any ingredient listed at the end of this leaflet; you have fluid overload or are overhydrated; you have swelling and ascitic cirrhosis (abnormal accumulation of fluid in the abdomen due to liver disease); you have heart failure; you have serious kidney problems where you are passing little or no urine; you have too much potassium, sodium, calcium or chlorides in your blood that is not being corrected with medication; you are taking digitalis (a heart medication); the expiry date printed on the pack is overdue. _YOU MUST TELL YOUR DOCTOR _ _IF YOU:_ have heart problem; have kidney problems including kidney stones ; are taking any other medicine including those you can buy without a prescription, in particular medicines for high blood pressure (diuretics, ACE inhibitors or ARAs), immunosuppressant medicines (tacrolimus or cyclosporin), carbenoxolone, corticosteroids or vitamin D are pregnant and have ‘preeclampsia’ (a serious condition in pregnancy that causes high blood pressure) HOW RINGER’S SOLUTION IV INFUSION IS GIVEN _HOW MUCH IT IS GIVEN:_ Your doctor will decide how much Ringer’s Solution IV Infusion will be given Pročitajte cijeli dokument
BAXTER RINGER’S SOLUTION FOR INTRAVENOUS INFUSION Version 1.1 1 of 11 AUSTRALIAN PRODUCT INFORMATION – BAXTER RINGER’S SOLUTION (SODIUM CHLORIDE, POTASSIUM CHLORIDE AND CALCIUM CHLORIDE DIHYDRATE) INJECTION FOR INTRAVENOUS INFUSION 1 NAME OF THE MEDICINE Sodium chloride, potassium chloride and calcium chloride dihydrate. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION The active ingredient in Baxter Ringer’s Solution for Intravenous (IV) Infusion (Ringer’s Solution) comprise sodium chloride (8.6 g/L), potassium chloride (0.3 g/L) and calcium chloride dihydrate (0.33 g/L) in Water for Injections. Baxter Ringer’s Solution is sterile and non-pyrogenic. There is no antimicrobial agent or buffer added. It is an isotonic intravenous solution with pH of 5.0 – 7.5 and an osmolality of 308 mOsm/kg. For the full list of excipients, see Section 6.1 List of Excipients. 3 PHARMACEUTICAL FORM Baxter Ringer’s Solution is a clear colourless solution for Intravenous Infusion. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Baxter Ringer’s Solution is indicated for restoring the loss of water and electrolytes as required by the clinical condition of the patient. 4.2 DOSE AND METHOD OF ADMINISTRATION Baxter Ringer’s Solution is for intravenous infusion as directed by the physician. The dosage, volume, rate and duration of administration of Baxter Ringer’s Solution is dependent upon the age, weight, clinical conditions of the patient and concomitant therapy, and administration should be determined by a physician experienced in intravenous fluid therapy. Fluid balance and plasma electrolyte concentrations (sodium, potassium, calcium and chlorides) must be monitored during administration. Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration whenever solution and container permit. Do not administer unless the solution is clear and seal is intact. Only sterile and nonpyrogenic equipment must be used for intravenous administration. As with all parenter Pročitajte cijeli dokument